行情

OMER

OMER

奥麦罗制药
NASDAQ

实时行情|Nasdaq Last Sale

14.88
-0.27
-1.78%
盘后: 14.80 -0.08 -0.54% 16:16 05/29 EDT
开盘
14.95
昨收
15.15
最高
15.07
最低
14.17
成交量
38.33万
成交额
--
52周最高
20.92
52周最低
8.50
市值
8.11亿
市盈率(TTM)
-8.5527
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测

分析师预测OMER价格均价为35.40，最高价位75.00，最低价为17.00。

EPS

OMER 新闻

更多
Edited Transcript of OMER earnings conference call or presentation 11-May-20 8:30pm GMT
Q1 2020 Omeros Corp Earnings Call
Thomson Reuters StreetEvents · 2天前
Omeros Gets Technical Rating Upgrade, Relative Strength Line Moves Up To 75
Investor's Business Daily · 4天前
Omeros: Some Concerns Remain... As Do Opportunities
Seeking Alpha - Article · 05/14 14:05
Omeros To Present Narsoplimab Pivotal Trial Data At European Hematology Association Annual Congress Jun. 11-14
Omeros Corporation (NASDAQ:OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will be presented at the
Benzinga · 05/14 13:07
Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress
Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will be presented at the 25th Annual Congress of the European He
Business Wire · 05/14 13:00
Omeros Corporation (OMER) CEO Greg Demopulos on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/12 01:37
Omeros EPS misses by $0.07, misses on revenue
Omeros (NASDAQ:OMER): Q1 Non-GAAP EPS of -$0.41 misses by $0.07; GAAP EPS of -$0.53 misses by $0.19. Revenue of $23.5M (+7.9% Y/Y) misses by $6.71M. Press
seekingalpha · 05/12 01:06
Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates
Omeros (OMER) delivered earnings and revenue surprises of -2.50% and -23.88%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/11 22:55

所属板块

生物技术和医学研究
+1.44%
制药与医学研究
+1.29%

热门股票

代码
价格
涨跌幅

OMER 简况

Omeros Corporation是一家商业阶段的生物制药公司。该公司主要从事针对大型市场与孤儿适应症的小分子与蛋白质疗法的发现、开发和商业化业务，以治疗补体介导的中枢神经系统的炎症、疾病与紊乱。该公司的药品OMIDRIA（去氧肾上腺素和酮咯酸眼内溶液）用于白内障手术或人工晶状体（IOL）置换术中。该公司的临床阶段发展计划的重点是补体相关的血栓性微血管病变、补体介导的肾小球肾病、亨廷顿舞蹈病与认知障碍以及成瘾性与强迫性疾病。该公司还提供多种临床前程序和平台，用于解锁新的G蛋白偶联受体（GPCR）药物靶标和生成抗体。
展开

微牛提供Omeros Corporation(NASDAQ-OMER)的股票价格，实时市场报价，专业分析师评级，深度图表和免费的OMER股票新闻，以帮助您做出投资决策。